	US 11,913,958 B2
	Compositions and methods for detecting lung cancer
Alexandre Prieur, Montpellier (FR)
Assigned to ECS-Progastrin SA, Prilly (CH)
Appl. No. 16/498,534
Filed by ECS-Progastrin SA, Prilly (CH)
PCT Filed Mar. 30, 2018, PCT No. PCT/EP2018/058332 § 371(c)(1), (2) Date Sep. 27, 2019, PCT Pub. No. WO2018/178354, PCT Pub. Date Oct. 4, 2018.
Claims priority of application No. 17305382 (EP), filed on Mar. 30, 2017.
Prior Publication US 2020/0103410 A1, Apr. 2, 2020
Int. Cl. G01N 33/574 (2006.01); C07K 16/26 (2006.01); C07K 16/22 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)

CPC G01N 33/57423 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/26 (2013.01); C07K 16/3023 (2013.01); C07K 16/32 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); G01N 2333/595 (2013.01)]

20 Claims

1. A method for the in vitro diagnosis of lung cancer in a subject, said method comprising:

a) obtaining a biological sample from said subject,

b) detecting whether progastrin is present in said biological sample by contacting said biological sample with at least one progastrin-binding molecule, wherein said progastrin-binding molecule is a monoclonal antibody produced by the hybridoma deposited at the CNCM, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris CEDEX 15, France, on 27 Dec. 2016, under reference 1-5158,

c) detecting the binding of said progastrin-binding molecule to progastrin in said biological sample,

d) detecting whether a lung cancer biomarker is present in said biological sample, and

e) diagnosing said subject with a lung cancer when the presence of progastrin and said lung cancer biomarker is detected.